Navigation Links
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Date:6/16/2009

PINE BROOK, N.J. and BASEL, Switzerland, June 16 /PRNewswire/ -- Elusys Therapeutics and Lonza Sales AG entered into an agreement for the production of Anthim(TM), a therapeutic monoclonal antibody in late stage development for the treatment of anthrax infection. Under this agreement, Lonza will provide process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System(TM).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01624LOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20090616/NY32818LOGO )

"Elusys is pleased to initiate a partnership with Lonza for the production of Anthim. Lonza has considerable experience in large-scale manufacturing of monoclonal antibodies and a well-established reputation with regulatory agencies for the production of licensed products," commented James Porter, Vice President of Development and Manufacturing at Elusys.

"Elusys has developed a very promising antibody therapeutic and we are proud to be able to support the further development of Anthim towards its commercial use," added Dr. Stephan Kutzer, Head of Lonza Biopharmaceuticals.

Anthim Background

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalation anthrax. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA. Elusys has been awarded $34 million from the National Institutes of Health and the Department of Defense for development of Anthim, of which $12 million was awarded in September 2007, under contract
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... 2014 Market Research Report ... Industry, 2009-2019 is a professional and in-depth ... (CAS 49562-28-9) industry. The report firstly reviews ... including its classification, application and manufacturing technology.The ... manufacturers of Fenofibrate (CAS 49562-28-9) listing their ...
(Date:9/21/2014)... “Cluster headaches are sometimes called ‘Suicide ... to resolve,” said Steve Young of Ew Publishing; “I’ve ... pain that is more intense.” , “It should be ... or migraines, that medical research is pointing to some ... added. , Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous biochemical ...
(Date:9/21/2014)... According to latest National Vital Statistics ... since 1966 (10.5 births per 1,000 women in 2013). Since ... risen steadily by 2 percent per year. The birth rate ... 50 and over) also rose, the first such increase since ... nine times as many first births to women aged 35 ...
(Date:9/20/2014)... Vegas, NV (PRWEB) September 21, 2014 ... improvement method developed by fitness expert Michael Wren that ... lose stubborn weight and reverse health conditions like high ... the attention of Shane Michaels, prompting an investigative review. ... loss methods and tips upside down by showing people ...
(Date:9/20/2014)... September 21, 2014 Increases in ... to greater waste treatment volumes. However, government regulations ... waste from landfill. According to IBISWorld industry analyst ... implemented strategies aimed at reducing the volume of ... recycled and recovered.” Still, a large proportion of ...
Breaking Medicine News(10 mins):Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3
... antibodies in migrant birds in five Siberian regions, a spokesman ... ,"Out of over 4,000 samples taken in the area this ... genetic material of the A-H5 virus and antibodies in their ... the presence of antibodies meant that either the birds had ...
... assess the effectiveness and tolerability of subdermal implantable contraceptives ... that they were all good at preventing pregnancy. ... be any more or less effective than the others ... effect with all the implants was changes in bleeding ...
... atrial fibrillation (AF) have irregular heart beats and have a ... (atria) of their hearts. These clots can then travel to ... ,One way of reducing the risk of this occurring is ... clots. Two commonly used options are anticoagulants that inhibit the ...
... smoking to secure peoples' rights to the highest standards of ... implementing a comprehensive anti-tobacco law to reduce the spread of ... Ali bin Shukur, Under-secretary of the Ministry of Health, was ... bill on smoking is being deliberated at the UAE Ministerial ...
... found in turmeric may help beat Alzheimer's, which is ... ,Researchers isolated the compound 'bisdemethoxycurcumin' found in turmeric, which ... the body against infections and diseases. ... patients and treat the incurable and fatal brain condition, ...
... six-month phase of a calorie-restriction study conducted at the ... Aging (USDA HNRCA) at Tufts University suggest that,accepting food ... important component of weight management. ,Supplemental results ... Restricting Intake of Energy (CALERIE) trial provide new insights ...
Cached Medicine News:Health News:Anticoagulants is Better for Atrial Fibrillation 2Health News:Food Cravings are Linked to Weight Managenemt 2Health News:Food Cravings are Linked to Weight Managenemt 3
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 /PRNewswire-iReach/ ... Chinese Oxybutynin Hydrochloride Industry, 2009-2019 is a ... and Chinese Oxybutynin Hydrochloride industry. The report ... Hydrochloride including its classification, application and manufacturing ... China,s top manufacturers of Oxybutynin Hydrochloride listing ...
(Date:9/19/2014)...  The board of directors of AbbVie Inc. (NYSE: ... of $0.42 per share.  The cash ... record at the close of business on Oct. 15, ... research-based biopharmaceutical company formed in 2013 following separation from ... dedicated people and unique approach to innovation to develop ...
(Date:9/19/2014)... -- Merck (NYSE: MRK ), known as MSD outside ... , is teaming with celebrity chef and cookbook author Leticia ... an educational program encouraging Hispanics with type 2 diabetes to achieve ... to help reduce the risk of serious health problems. Hispanics in ... risk for developing type 2 diabetes than non-Hispanic white adults, and ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5
... (vRad), a technology-enabled national radiology practice, announced ... Radiology Associates (MRA) have joined its Pennsylvania-based ... (DII). These former MRA radiologists will continue ... and join the more than 60 DII ...
... 2011  The Austen BioInnovation Institute in Akron (ABIA) ... today a strategic partnership to share expertise while ... The partnership combines the polymer ... of ABIA with Lubrizol, a key medical polymer ...
Cached Medicine Technology:vRad Radiology Alliance Continues to Transform Radiology With Most Recent Practice Partnership 2Austen BioInnovation Institute and Lubrizol Announce New Strategic Innovation Partnership 2Austen BioInnovation Institute and Lubrizol Announce New Strategic Innovation Partnership 3
Launcher Coronary Guide Catheter gives a dependable platform for optimal outcomes with absolute visualization and a proprietary design....
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
... Fast-Cath, Maximum, Maximum Xtra, and ... line of standard and specialty hemostasis ... recognized as the premier hemostasis introducers ... electrophysiology procedures including angiography, angioplasty, stenting, ...
New system has all of the features of the EPT-1000TC. Now with 100 watts RF power using the Blazer II XP catheter....
Medicine Products: